Corrigendum: Optimized riboswitch-regulated AAV vector for VEGF-B gene therapy

[This corrects the article DOI: 10.3389/fmed.2022.1052318.].

Saved in:
Bibliographic Details
Published inFrontiers in medicine Vol. 10; p. 1143748
Main Authors Eriksson, Reetta A E, Nieminen, Tiina, Galibert, Lionel, Peltola, Sanna K, Tikkanen, Petra, Käyhty, Piia, Leinonen, Hanna M, Oruetxebarria, Igor, Lepola, Saana, Valkama, Anniina J, Lipponen, Eevi M, Lesch, Hanna P, Ylä-Herttuala, Seppo, Airenne, Kari J
Format Journal Article
LanguageEnglish
Published Switzerland Frontiers Media S.A 03.03.2023
Subjects
AAV (adeno-associated virus)
gene therapy
Medicine
ON-switch
riboswitch
tetracycline
VEGF-B
AAV (adeno-associated virus)
riboswitch
transgene expression regulation
gene therapy
tetracycline
ON-switch
VEGF-B
Online AccessGet full text

Cover

More Information
Summary:[This corrects the article DOI: 10.3389/fmed.2022.1052318.].
Bibliography:corrigendum
SourceType-Other Sources-1
content type line 63
ObjectType-Correction/Retraction-1
These authors have contributed equally to this work
This article was submitted to Gene and Cell Therapy, a section of the journal Frontiers in Medicine
Approved by: Frontiers Editorial Office, Frontiers Media SA, Switzerland
ISSN:2296-858X
2296-858X
DOI:10.3389/fmed.2023.1143748